Skip to Content

WORLD OF GENERIC DRUGS MODULE

  1. Is FDA planning to organize international training around quality by design?
    1. Training opportunities are part of the International Conference on Harmonization (ICH). FDA is putting together an implementation team for Q8, 9 and 10. FDA is also developing fact sheets for Q8, 9, 10, and a program that will standardize training throughout the world.
  2. How many design space applications has FDA approved?
    1. The Office of Generic Drugs has not done a complete design space. OGD has decided it needs to address design space issues in a rational, timely manner.
  3. Does FDA accept applications for change of manufacturing sites for formulation, not of the active pharmaceutical ingredient? Is this considered a completely new application?
    1. To clarify, the formulation is the same, but it is manufactured at a different site. The firm will need to provide additional data for this change. The data will be evaluated for bioequivalence and chemistry, and may undergo a compliance inspection. In addition, the company will have to redo its bioequivalence data to link it to the original application.
Lesson status: Incomplete (0% done)
Topic: page 5 of 5 (Lesson: page 26 of 27)